{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:04:29Z","timestamp":1790877869279,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xkme.2026.101497","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:17:18Z","timestamp":1786547838000},"page":"101497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0136-8627","authenticated-orcid":false,"given":"Thea Tanderup","family":"Kj\u00e6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lindhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Hammerich","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Birn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-5566","authenticated-orcid":false,"given":"Lars Holger","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2026.101497_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.xkme.2026.101497_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney International"},{"key":"10.1016\/j.xkme.2026.101497_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102615","article-title":"Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study","volume":"72","author":"Chadban","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xkme.2026.101497_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41581-024-00863-9","article-title":"The impact of population ageing on the burden of chronic kidney disease","volume":"20","author":"Chesnaye","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.xkme.2026.101497_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12875-023-02077-7","article-title":"Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death","volume":"24","author":"Borg","year":"2023","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.xkme.2026.101497_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf147","article-title":"Occurrence and prognosis of chronic kidney disease in Denmark \u2013 a nationwide population-based cohort study","volume":"18","author":"Jensen","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2026.101497_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101497_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101497_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101497_bib10","article-title":"Cronical Kidney Disease - Analysis Methods for Determining Glomerular Filtration Rate and Albuminuria (Part 1), along with Recommendations for the Clinical Evaluation, Treatment, and Monitoring of Chronic Kidney Disease (Part 2)","year":"2024","journal-title":"Danish Nephrology Society"},{"key":"10.1016\/j.xkme.2026.101497_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae393","article-title":"The management of chronic kidney disease in primary care in Denmark: patient characteristics, treatment, follow-up, progression and referral","volume":"18","author":"Birn","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2026.101497_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12875-025-02721-4","article-title":"Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study","volume":"26","author":"Lindhardt","year":"2025","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.xkme.2026.101497_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae025","article-title":"Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial","volume":"17","author":"McEwan","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2026.101497_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101497_bib17","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40273-019-00835-z","article-title":"Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design","volume":"37","author":"Sugrue","year":"2019","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.xkme.2026.101497_bib23","article-title":"In Denmark kidney transplantation is more cost-effective than dialysis","volume":"61","author":"Jensen","year":"2014","journal-title":"Dan Med J"},{"key":"10.1016\/j.xkme.2026.101497_bib24","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside ckd research programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.xkme.2026.101497_bib27","series-title":"Samfunds\u00f8konomisk Gevinst Ved Nyretransplantation","year":"2017"},{"key":"10.1016\/j.xkme.2026.101497_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/cer.15.68","article-title":"Incidence and cost of hypoglycemic events requiring medical assistance in a hospital setting in Denmark","volume":"5","author":"Lyngsie","year":"2016","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.xkme.2026.101497_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165675","article-title":"Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study","volume":"11","author":"Jesky","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xkme.2026.101497_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/089686080202200107","article-title":"Comparison of hemodialysis and peritoneal dialysis \u2014 a cost\u2013utility analysis","volume":"22","author":"Sennf\u00e4lt","year":"2002","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.xkme.2026.101497_bib31","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1185\/030079905X65277","article-title":"Characterisation and comparison of health-related quality of life for patients with renal failure","volume":"21","author":"Lee","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.xkme.2026.101497_bib32","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0272989X16638312","article-title":"Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events","volume":"36","author":"Briggs","year":"2016","journal-title":"Med Decis Making"},{"key":"10.1016\/j.xkme.2026.101497_bib33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101497_bib34","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"European J of Heart Fail"},{"issue":"4","key":"10.1016\/j.xkme.2026.101497_bib35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value in Health"},{"key":"10.1016\/j.xkme.2026.101497_bib36","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/030079906X115757","article-title":"Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes","volume":"22","author":"Currie","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.xkme.2026.101497_bib37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0272989X16658660","article-title":"The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes","volume":"36","author":"Peasgood","year":"2016","journal-title":"Med Decis Making"},{"key":"10.1016\/j.xkme.2026.101497_bib38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Medical Decision Making"},{"key":"10.1016\/j.xkme.2026.101497_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/23814683231159023","article-title":"Catalog of EQ-5D-3L health-related quality-of-life scores for 199 chronic conditions and health risks in Denmark","volume":"8","author":"Hvidberg","year":"2023","journal-title":"MDM Policy & Practice"},{"key":"10.1016\/j.xkme.2026.101497_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/14737167.2024.2420654","article-title":"Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors in the treatment of chronic kidney disease: a systematic review","volume":"25","author":"Toan","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.xkme.2026.101497_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae351","article-title":"Sex-specific temporal trends in incidence and prevalence of chronic kidney disease: a Danish population-based cohort study","volume":"18","author":"Vestergaard","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.xkme.2026.101497_bib43","author":"Svensson"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:32:59Z","timestamp":1790875979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2590059526002591"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101497","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101497"}}